

**CURRICULUM VITAE RANDALL K.
GIBB, MD, MHA, FACOG**

Telephone Number:

Cell: 406-696-2696

Present Position:

2017-May 2019 Chief Executive Officer
2014-2016 Chief Medical Officer, Clinic, Billings Clinic
2010-2014 Medical Director, Billings Clinic Cancer Center
2006-2015 Department Chair, Gynecologic Oncology
Billings Clinic Cancer Center
2006-2010 Vice Chair, Billings Clinic Cancer Center

Education:

Undergraduate: 1983-1987 B.S. University of Illinois Champaign, Illinois

Graduate: 1987-1991 M.D. Loyola University, Chicago Stritch School of
Medicine Maywood, Illinois

Postgraduate: 1991-1995 Resident in Obstetrics and Gynecology
St. Louis University School of Medicine
St. Louis, Missouri

1995-1998 Fellowship in Gynecologic Oncology University of Louisville
School of Medicine Louisville, Kentucky Master:

2017- 2019 Executive Master of Health Administration University of
Southern California Sol Price School of Public Policy

Los Angeles,
California GPA 4.0

Academic Positions/Employment:

1995-1998 Lecturer, Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of Louisville School of Medicine
Louisville, Kentucky

1998-2000 Instructor, Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of Louisville School of Medicine
Louisville, Kentucky

1999-2000 Acting Director, Division of Gynecologic Oncology
University of Louisville School of Medicine
Louisville, Kentucky

2000-2006 Assistant Professor, Division of Gynecologic Oncology
Washington University School of
Medicine St. Louis, Missouri

2004-2006 Adjunct Assistant Professor Women
and Gender Studies Washington University in St.
Louis St. Louis, Missouri

2006 Associate Professor, Division of Gynecologic Oncology
Washington University School of
Medicine St. Louis, Missouri

2006-2013 Adjunct Associate Professor, Division of Gynecologic Oncology
Washington University School of
Medicine St. Louis, Missouri

2012-2014 Clinical Associate Professor

Department of Obstetrics and Gynecology
University of Washington School of
Medicine

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 3

University Appointments and Committees:

University and Hospital Appointments:

Washington University School of Medicine Barnes Jewish Hospital
Missouri Baptist Medical Center Siteman Cancer Center, Research

Member Committees:

1986-1987 Intra-Fraternity Council Representative

1986-1987 Liberal Arts and Science Council

1987-1989 Member of the Pi Kappa Phi Housing Corporation
Board of Directors

1988 Stritch Financial Aid Committee

1988-1991 Loyola Committee on Student Life

1999-2000 Faculty Senate

University of Louisville School of Medicine

2001-2006 Human Studies Committee (HSC)

Washington University Medical Center

2001-2006 Hospital Epidemiology & Infection Control Committee

Barnes Jewish

Hospital

2002-2006 Information Technology Committee

Departments of Surgery and

OB/GYN

2004-2006 Missouri Baptist OB/GYN Quality Control/

Peer Review Committee

Missouri Baptist Hospital

2004-2006 Protocol Review and Monitoring Committee (PRMC)

Siteman Cancer Center

2005-2006 Electronic Medical Records Steering Committee

Washington University School of

Medicine

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 4

Current Hospital Appointments and Committees:

Hospital

Appointments:

Billings Clinic

Hospital Committees:

2006-2015 Cancer Committee, Billing Clinic

2007-2014 Obstetrics and Gynecology Department, Billings Clinic
Annual Symposium Committee

2007-2016 Operating Room Council, Billings Clinic

2008-2016 Robotic Steering Committee, Billings Clinic

2009-2016 Clinical Referral Task Force Committee, Billings Clinic

2010-2016 Physician EMR Governance Group, Billings Clinic

2011-2014 Human Studies/Institutional Review Board, Billings Clinic

2011-2016 Cancer Committee, Billings Clinic Cancer Liaison Physician

2011-Present Complexity and Clinical Care Network, Billings Clinic

2012-2017 Medical Executive Committee, Billings Clinic

2014-2017 Serious Safety Event Review Committee

2016-2017 Peer Review Committee

National and Professional Organization and Society Appointments:

1983-1987 Pi Kappa Phi Fraternity, Upsilon Chapter 1985 P.U.S.H. Chairman
1986 Warden 1987 President 1998 Society of Gynecologic Oncologists 2004
Program Committee, 35th Annual Meeting: Improving the Care
of Women with Gynecologic Cancer

1998-2013 Gynecologic Oncology Group

2003-2007 Cervix Committee

1998 International Gynecologic Cancer Society American
Association for Cancer Research (termed 2019) American
Medical Association American Society Clinical Oncology

1999 Fellow, American College of Obstetricians & Gynecologists

1999-2000 Cancer Committee, Kentucky Medical Association

2000 Missouri State Medical Society

St. Louis Metropolitan Medical Society

2000 St. Louis Gynecological Society

2003-2005 Counselor 2005-2006

President-Elect 2006-2007 President

2000 St. Louis Maternity Hospital Society 2001

Secretary 2002 Treasurer 2003 President

2003 Program Committee (2004 Annual Meeting)

Society of Gynecologic
Oncology

2004 Program Committee (2004 Annual Meeting)

Western Association of Gynecologic
Oncology

2006-2007 Gynecologic Oncology Group

Developmental Therapeutics Member

2006-2009 ASCO/SGO Liaison Task Force

Society of Gynecologic
Oncology

2007 Montana Cervical Cancer Task Force Chair

2007-2009 International Committee

Society of Gynecologic
Oncology

2007-2009 Clinical Practice Committee

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 6

Society of Gynecologic
Oncology

2009-2011 Clinical Practice Committee Vice Chair

Society of Gynecologic
Oncology

2009-2011 Government Relations Committee

Society of Gynecologic Oncology

2009-2011 Surgical Quality Alliance

American College of
Surgeons

2010-Present Quality and Outcomes Committee

Society of Gynecologic Oncology

2010-Present Uterine Task Force Committee

National Cancer Institute

2011-2013 Clinical Practice Committee Chair

Society of Gynecologic Oncology

2011-2012 Society of Gynecologic Oncology Executive Committee
Ex-officio Member, Clinical Practice Chair

2011-Present Congressional Ambassador Member

2013 Nominating Committee
Society of Gynecologic
Oncology

2013 Program Committee (2013 Annual Meeting)
Western Association of Gynecologic
Oncology

2013-2016 American College of Obstetricians and Gynecologists
Montana Section Secretary-Treasurer

2014-Present NCORP National Community Oncology Program

2014-2016 Western Association of Gynecologic Oncology
WAGO Executive Committee Member at Large

2014 National Cancer Institute Uterine Clinical Trails Planning Team

2014-Present Society of Gynecologic Oncology
Clinical Outcomes Taskforce Member

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 7

2014-2017 Society of Gynecologic Oncology
Finance Committee Member

2014-2017 Montana Medical Association, CMO Council Member

2014-Present American Medical Association

Integrated Physician Practice Section Member

2015-2019 American Medical Association

Integrated Physician Practice Section Board Member
Small to Medium Group Size

2015–2019 Billings Chamber Board of Directors

Board
Member

2016-2017 Western Association of Gynecologic Oncology

WAGO Executive Committee Vice President

2016-2019 American College of Obstetricians and Gynecologists

Montana Section Vice Chair

2018-2019 Montana Hospital Association Board of Directors

Member at
Large

2018-2019 Big Sky Care Connect Board of Directors

Chair Statewide
HIE effort

2019- present American College of Obstetricians and Gynecologists

Montana Section Chair

Medical Licensure and Board Certification:

Licensure:

Missouri 102525

Montana 11241

Board

Certification:

1999 Diplomat, American Board of Obstetrics and Gynecology 2001
Subspecialty Board Certified-Gynecologic Oncology

**Honors and
Awards:**

Dean's List

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 8

John E. Groening Scholarship Illinois State Scholarship Optimist Club
Scholarship 1987 Pi Kappa Phi Brother of the Year 1995 Academic Chief
Resident, St. Louis University 2000-2005 Excellence in Teaching Award,
Department of Obstetrics And
Gynecology, Washington University School of Medicine 2001-2006
Faculty Resident Teaching Award 2003 Teacher of the Year, Dept. of
Obstetrics and Gynecology, Washington University School of Medicine
2019 Upsilon Phi Delta, Health Administration Honor Society
University of Southern California, GPA
4.0

**Editorial
Responsibilities:**

Reviewer, Journal of Gynecologic Oncology
Reviewer, Journal of American College of
Surgeons Reviewer, Journal of Cancer Letters
Reviewer, Gynecologic and Obstetric Investigation

**Major Invited Professorships and
Lectureships:**

June 1995 "Apoptosis: Its Current Implications in Cancer Chemotherapeutics." Grand
Rounds, Department of Obstetrics and Gynecology, St. Louis University Hospital. St.
Louis, Missouri

November 1996 “Vulvar Cancer in the 1990’s.” Grand Rounds, Department of Obstetrics and Gynecology, University of Louisville School of Medicine. Louisville, Kentucky

March 1998 “Gene Therapy in Gynecologic Malignancies: Buck Rogers Meets the 21st Century.” Grand Rounds, Department of Obstetrics and Gynecology, University of Louisville School of Medicine. Louisville, Kentucky

December 1998 “Deep Venous Thrombosis (DVT) and Pulmonary Embolism: Prevention and Management.” Grand Rounds, Department of Obstetrics and Gynecology, University of Louisville School of Medicine. Louisville, Kentucky

October 2000 “Molecular Biology for the Generalist.” 26th Annual Symposium on Obstetrics & Gynecology, Washington University School of Medicine. St. Louis, Missouri

November 2000 “Non-surgical Management of Cervical Cancer.” Fall Cancer

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 9

Symposium, Regional Cancer Center at Southeast Missouri Hospital. Cape Girardeau, Missouri

October 2001 “Intraoperative Complications: How to Avoid Them and How to Fix Them.” 27th Annual Symposium on Obstetrics & Gynecology, Washington University School of Medicine. St. Louis, Missouri

April 2002 “Gynecologic Malignancies.” 1st Annual Siteman Cancer Center Oncology Nursing Symposium, Washington University School of Medicine. St. Louis, Missouri

October 2002 “New Advances in Ovarian Cancer Detection and Treatment.” 28th Annual Symposium on Obstetrics & Gynecology, Washington University School of Medicine.

St. Louis, Missouri April 2003 “Importance of Co-Morbidity in Gynecologic Surgery.” 1st Annual Gynecologic Cancer Conference, Washington University School of Medicine. St. Louis, Missouri

October 2003 “Diagnosis and Management of Postoperative and Complex Pelvic Infections.” 29th Annual Symposium on Obstetrics & Gynecology, Washington University School of Medicine. St. Louis, Missouri

November 2003 “Are We Making Progress in Treating Women’s Cancer? Update 2003.” Recent Advances in the Control of Nausea-Targeting the Chemoreceptor Trigger Zone. City of Hope Las Vegas, Nevada

February 2004 “The Next Generation Pap: HPV, ALTS and ACOG Guidelines: What Does It All Mean?” Grand Rounds, Howard University Hospital, Department of Obstetrics and Gynecology. Washington, D.C.

March 2004 “Women’s’ Health Issues: Cervical Cancer Screening and STD’s.” St. Louis Nurses in Advanced Practice (SNAP). St. Louis, Missouri

April 2004 “The Changing Times for Pap Management.” 2004 Missouri State Family Planning Conference. Family Planning: Connecting Communities with Services. Jefferson City, Missouri

April 2004 “Cervical Cancer Screening.” 2nd Annual Gynecologic Cancer Conference, Washington University School of Medicine. St. Louis, Missouri

October 2004 “The Impact of New Pap Technologies on Clinical Management.” Grand Rounds, Department of Obstetrics and Gynecology, University of Illinois. Peoria, Illinois

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 10

October 2004 “HPV Testing: How, When, and Why?” 30th Annual Symposium on
Obstetrics and Gynecology, Washington University School of Medicine. St. Louis, Missouri
November 2004 “Cervical Cancer: Current Treatment and Management.” Grand Rounds,
Department of Medicine, Scott Air Force Base. Shiloh, Illinois

October 2005 “Assessing Technologies: The Pathway to Cervical Cancer Screening.
The Role of Liquid-Based Cytology for Cervical Cancer
Screening.” 1st Beijing International Conference on Obstetrics and
Gynecology. Beijing, China

November 2005 “Ovarian Cancer: Treatment Recommendations and New Horizons.”
Visiting Professor of Oncology, Munson Medical Center,
Traverse City, Michigan

February 2013 “Update on Endometrial Cancer” The American Congress of Obstetricians
and Gynecologists Montana Section Annual Clinical Meeting at Big
Sky

August 2018 “Process Improvement is Key to Transforming Healthcare” 21st Annual Saint
Louis University Obstetrics and Gynecology Residents’ Research Symposium
and Annual Raul Artal, MD Invited Lecture presented by the Department of
Obstetrics, Gynecology and Women’s Health, Saint Louis University School of
Medicine and SSM | St. Mary’s Hospital, St. Louis, MO

October 2018 “Vulvar Disease and Therapy for Pre-Invasive Vulvar Lesions” Washington
University 44th Annual OB/GYN Symposium, Department of Obstetrics &
Gynecology, Washington University, St. Louis, MO

October 2018 “Business of Medicine: Future of Healthcare in Rural Communities”
Washington University 44th Annual OB/GYN Symposium, Department of
Obstetrics & Gynecology, Washington University, St. Louis, MO

**Research
Support:**

Non-governmental

:

1. Gibb RK, Taylor DD, Gercel-Taylor C, Yashar CM, Hilgers RD. Defining the inhibitory effects of RU486 (Mifepristone) on endometrial carcinoma cell lines for the clinical treatment of endometrial carcinoma. Principal Investigator. Alliant Community Trust Fund, \$49,000.

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 11

2. Gercel-Taylor C, Doering DL, O'Connor DM, Gibb RK, Yashar CM, Taylor D. Clinical correlation of apoptosis as a marker of chemosensitivity in ovarian cancer. Co-investigator. Alliant Community Trust Fund, \$49,000.
3. Doering DL, Gibb RK. Phase II: Non-randomized study of LY353381 HCl in patients with recurrent or advanced endometrial cancer. Lilly Research Laboratories, A Division of Eli Lilly & Co., \$50,385
4. Gibb RK, Doering DL, Pursell S. Phase III: Clinical evaluation of once weekly dosing of PROCRIT in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Ortho Biotec Inc., \$1,250 per patient.

Peer Reviewed Publications:

1. Gibb RK, Taylor DD, Wan T, O'Connor DM, Doering DL, Gercel-Taylor C. Apoptosis as a measure of chemosensitivity to cisplatin and Taxol therapy in ovarian cancer cell lines. *Gynecol Oncol* 1997; 65(1):13-22.
2. Yashar CM, Taylor DD, Gibb RK, Gercel-Taylor C. Lymphokine-activated killer (LAK)-mediated lysis of sequentially isolated ovarian cancer cell lines. *Gynecologic Oncology* 1997; 38:431-437.

3. Yashar CM, Gercel-Taylor C, Gibb RK, Weeks JW, Taylor DD. Identification of a unique form of p53 in human cord blood associated with the development of maternal autoantibodies. *American Journal of Reproductive Immunology* 1998; 39(6):368-375.
4. Schneider CC, Gibb RK, Taylor DD, Gercel-Taylor C. Inhibition of endometrial cancer cell lines by RU486 (mifepristone). *Journal for the Society of Gynecologic Investigation* 1998; 5(5):334-338.
5. Katsanis WA, O'Connor DM, Gibb RK, Bendon RW. Endometrial stromal sarcoma involving the placenta. *Annals of Diagnostic Pathology* 1998; 2(5):301-305.
6. Makhija S, Taylor DD, Gibb RK, Gercel-Taylor C. Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids. *International Journal of Oncology* 1999; 14(3):515-521.
7. Gibb RK, Gercel-Taylor C. Use of diphenylamine in the detection of apoptosis. In Bartlett J (ed). *Methods in Molecular Medicine - Ovarian Cancer: Methods and Protocols*. Towana, NJ: Humana Press, 1999.
8. Horowitz N, Pinto K, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Bocker-Edmonston T, Goodfellow PJ. Microsatellite instability, MLH1 promoter methylation, and loss of mismatch

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 12

repair in endometrial cancer and concomitant atypical hyperplasia. *Gynecologic Oncology* 2002 Jul; 86(1):62-68.

9. Cohn DE, Dehdashti F, Gibb RK, Mutch DG, Rader JS, Siegel BA, Herzog TJ. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. *Gynecologic Oncology* 2002; 85(1):179-184.
10. Horowitz NS, Gibb RK, Menegakis NE, Mutch DG, Rader JS, Herzog TJ. Utility and

cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients. *Obstetrics and Gynecology* 2002; 99(5):771-776.

11. Horowitz NS, Cohn DE, Herzog TJ, Mutch DG, Rader JS, Bhalla S, Gibb RK. The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies. *Gynecologic Oncology* 2002; 86(1):79-84.
12. Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, Look K, Walls KC, Fan M-Y, Mutch DG. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. *Proceedings of the National Academy of Sciences of the United States of America* 2003; 100(10): 5908-5913.
13. Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Goodfellow PJ. Frequent HOXA11 and THBS2 promoter methylation and a methylator phenotype in endometrial adenocarcinoma. *Clinical Cancer Research* 2003; 9(6):2277-2287.
14. Wright JD, Herzog TJ, Mutch DG, Gibb RK, Rader JS, Davila RM, Cohn DE. Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies. *Gynecologic Oncology* 2003; 91(1):134-138.
15. Buttin BM, Powell MA, Mutch DG, Rader JS, Herzog TJ, Gibb RK, Huettner P, Edmonston TB, Goodfellow PG. Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. *Clinical Cancer Research* 2004; Jan 15;10(2):481-490.
16. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Huettner PC, Herzog TJ. Synchronous ovarian metastases at the time of laparotomy for colon cancer. *Gynecologic Oncology* 2004; 92(3):851-855.
17. Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC, Edmonston TB, Herzog TJ, Rader JS, Gibb RK, Whelan AJ, Goodfellow PJ. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. *American Journal of Human Genetics* 2004; 74(6):1262-1269.

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 13

18. Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. *Gynecologic Oncology* 2004; 94(1):67-73.
19. Wright JD, Powell MA, Herzog TJ, Mutch DG, Rader JS, Gao F, Gibb RK. Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms. *Gynecologic Oncology* 2004; 94(2):436-441.
20. Horowitz, NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, Grigsby PW, Siegel BA, Mutch DG. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. *Gynecologic Oncology* 2004; 95(3):546-551.
21. Wright JD, Gibb RK, Geevarghese S, Powell MA, Herzog TJ, Mutch DG, Grigsby PW, Gao F, Trimkaus KM, Rader JS. Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. *Cancer* 2005; 103(1):85-91.
22. Wright JD, Li J, Gerhard DS, Zhang Z, Huettner PC, Powell MA, Gibb RK, Herzog TJ, Mutch DG, Trinkaus KM, Rader JS. Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. *Gynecologic Oncology* 2005; 98(1):84-91.
23. Lamoreaux WT, Grigsby PW, Dehdashti F, Zoberi I, Powell MA, Gibb RK, Rader JS, Mutch DG, Siegel BA. FDG-PET evaluation of vaginal carcinoma. *International Journal of Radiation Oncology, Biology and Physiology* 2005; 62(3):733-737.
24. Wright JD, Davila RM, Pinto KR, Merritt DF, Gibb RK, Rader JS, Mutch DG, Gao F, Powell MA. Cervical dysplasia in adolescents. *Obstetrical Gynecology* 2005; 106(1):115-120.
25. Wright JD, Rosenblum K, Huettner PC, Mutch DG, Rader JS, Powell MA, Gibb RK. Cervical

sarcomas: An analysis of incidence and outcome. *Gynecologic Oncology* 2005; 99(2):348-351.

26. Lewin SN, Buttin BM, Powell MA, Gibb RK, Rader JS, Mutch DG, Herzog TJ. Resource utilization for ovarian cancer patients at the end of life: how much is too much? *Gynecologic Oncology* 2005; 99(2):261-266.
27. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Gao F, Herzog TJ. Relationship of ovarian neoplasms and body mass index. *Journal of Reproductive Medicine* 2005; 50(8):595-602.
28. Wright JD, Dehdashti F, Herzog TJ, Mutch DG, Huettner PC, Rader JS, Gibb RK, Powell MA, Gao F, Siegel BA, Grigsby PW. Preoperative lymph node staging of early-stage cervical carcinoma by [(18) F]-fluoro-2-deoxy-D-glucose-positron emission tomography. *Cancer* 2005 Dec 1; 104(11):2484-2491.

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 14

29. Taylor NP, Gibb RK, Powell MA, Mutch DG, Huetner PC, Goodfellow PJ. Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas. *Gynecologic Oncology* 2006; 100(1):107-110.
30. Wright JD, Rosenbush EJ, Powell MA, Rader JS, Mutch DG, Gibb RK. Long-term outcome of women who undergo panniculectomy at the time of gynecologic surgery. *Gynecologic Oncology* 2006 Jul; 102(1):86-91. Epub 2006 Jan 10.
31. Wright JD, Rader JS, Davila R, Powell MA, Mutch DG, Gao F, Gibb RK. Human papillomavirus triage for young women with atypical squamous cells of undetermined significance. *Obstetrics and Gynecology* 2006 Apr; 107(4):822-9.
32. Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, Rader JS. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. *Gynecologic Oncology* 2006

Nov; 103(2):489-93. Epub 2006 May 2. 33. Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA.

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. *Cancer* 2006 Jul 1; 107(1):83-89.

34. Taylor NP, Powell MA, Gibb RK, Rader JS, Huettner PC, Thibodeau SN, Mutch DG, Goodfellow PJ. MLH3 mutation in endometrial cancer. *Cancer Research* 2006 Aug 1; 66(15):7502-7508.

35. Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. *Gynecologic Oncology* 2006 Oct; 103(1):212-218. Epub 2006 May 3. 36. Taylor NP, Zigelboim I, Huettner PC, Powell MA, Gibb RK, Rader JS, Mutch DG, Edmonston

TB, Goodfellow PJ. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. *Modern Pathology* 2006; October 19 (10):1333-1338. Epub 2006 June 30. Erratum in: *Mod Pathol.* 2006 Nov; 19(11):1520.

37. Buttin BM, Powell MA, Goodfellow PJ, Lewin SN, Gibb RK, Mutch DG. Increased risk For abnormalities on perioperative colon screening in patients with microsatellite instability-positive endometrial carcinoma. *Int J Gynecol Cancer.* 2006 Nov-Dec; 16(6):1980-6.

38. Baum ME, Rader JS, Gibb RK, McAlister RP, Powell MA, Mutch DG, Gao F, Wright JD. Colposcopic accuracy of obstetrics and gynecology residents. *Gynecol Oncol.* 2006 Dec;103(3):966-70.

39. Zigelboim I, Taylor NP, Powell MA, Gibb RK, Rader JS, Mutch DG, Grigsby PW. Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy. *Radiat Med.* 2006 Nov; 24(9):625-30. Epub 2006 Nov 24.

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 15

40. Fayed A, Mutch DG, Rader JS, Gibb RK, Powell MA, Wright JD, Elnaqa I, Zoberi I, Grigsby PW. Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endo-metrial

- carcinoma. *Int J Radiat Oncol Biol Phys*. 2007 Feb 1; 67(2):480-4. Epub 2006 Dec 4.
41. McCourt CK, Mutch DG, Gibb RK, Rader JS, Goodfellow PJ, Trinkaus K, Powell MA. Body mass index: Relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. *Gynecol Oncol*. 2007 Mar; 104(3):535-9. Epub Nov 14.
42. Zigelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, Mutch DG. Micro-satellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. *J Clin Oncol*. 2007 May 20; 25(15):2042-8.
43. Wright JD, Grigsby PW, Rader JS, Mutch DG, Powell MA, Gao F, Gibb RK. Effect of a T0 radical hysterectomy specimen on survival for early stage cervical cancer. *Gynecol Oncol*. 2007 Nov; 107(2):280-4. Epub 2007 Aug 14.
44. Horowitz NS, Hua J, Powell MA, Gibb RK, Mutch DG, Herzog TJ. Novel cytotoxic Agents from an unexpected source; bile acids and ovarian tumors apoptosis. *Gynecol Oncol*. 2007 Nov; 107(2):334-9. Epub 2007 Aug 27.
45. Wright JD, Grigsby PW, Brooks R, Powell MA, GIBB RK, Gao F, Rader JS, Mutch DG. Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. *Cancer*. 2007 Sept 15; 110(6):1281-6.
46. Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK. Bevacizumab therapy in patients with recurrent uterine neoplasms. *Anticancer Res*. 2007 Sep-Oct; 27(5B):3525-8.
47. Tierney RM, Powell MA, Mutch DG, Gibb RK, Rader JS, Grigsby PW. Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer. *Radiat Med*. 2007 Nov; 25(9):439-45. Epub 2007 Nov 26.
48. Zhang Z, Borecki I, Nguyen L, Ma D, Smith K, Huettner PC, Mutch DG, Herzog TJ, Gibb RK, Powell MA, Grigsby PW, Massad LS, Hernandez E, Judson PL, Swisher EM, Crowder S, Li J, Gerhard DS, Rader JS. CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. *Cancer Res*. 2007 Dec 1; 67(23):11202-8.
49. Wright JD, Secord AA, Numnum TM, Rocconi RP, Powell MA, Berchuck A, Alvarez RD, Gibb RK, Trinkaus K, Rader JS, Mutch DG. A multi-institutional evaluation of factors predictive of toxicity and efficacy of Bevacizumab for recurrent ovarian cancer. *Int J Gynecol Cancer* 2008; 18, 400-406.

50. Nguyen TT, Wright JD, Powell MA, Gibb RK, Rader JS, Allsworth JE, Mutch DG. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. *Int J Gynecol Cancer*. 2008 Nov-Dec;18(6):1194-9. Epub 2008 Jan 23.

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 16

51. Herzog TJ, Powell MA, Rader JS, Gibb R, Lippmann L, Coleman RL, Mutch DG. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. *Gynecol Oncol*. 2008 Dec; 111(3): 467-73, doi: 10.1016/j.ygno.2008.08.005. Epub 2008 Oct 1.

52. Zigelboim I, Schmidt AP, Gao F, Thaker PH, Powell MA, Rader JS, Gibb RK, Mutch Dg, Goodfellow PJ. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. *J Clin Oncol*. 2009 Jul 1;27(19):3091-3096.

53. Harmandayan GZ, Gao F, Mutch DG, Virgo, KS, Gibb RK, Johnson FE. Ovarian cancer patient surveillance after curative-intent initial treatment. *Gynecol Oncol*, 2011 Feb: 120 (2):205-208.

54. Gibb RK. The use of liquid-based cytology in cervical cancer screening. *Rev Obstet Gynecol*. 2011;4(Suppl 1):S1.

55. Gibb RK, Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. *Rev Obstet Gynecol*. 2011;4(Suppl 1):S2-S11.

56. Alvarex RD, Gray HJ, Timmins PF 3rd. Gibb RK, Edelson M, Fowler JM, Havrilesky LJ, McCauley DL, Nash JD, Rahaman J, Rash JK, Rodabaugh KJ, Powell MA, Bristow RE, Brown JV, Tewari D, Cliby WA, Anastasia P, Robinson WR 3rd, Shahin MS, Cantrell LA, Cloven NG, Gold MA, Hope JM, Muntz HG, Sorosky JI, Elkas JC, Frumovitz MM, Jewell E, Spillman MA, Naumann RW. We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies. *Gynecol Oncol*. 2013 Apr;129(1):3-4. No abstract

available.

57. Chen, L; Cohn, D; Fishman, D; Gibb RK; Mutch, D; Olawaiye, A; Soper, D. Lynch Syndrome. American College of Obstetricians and Gynecologists Practice Bulletin. Number 147, November 2014.
58. Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, Borowsky ME, Gibb RK.
Society Of Gynecologic Oncology Recommendations For The Prevention Of Ovarian Cancer. Cancer. 2015 Jul 1;121(13):2108-20. doi: 10.1002/cncr.29321. Review.
59. Akshar Y. Patel, Anit K. Behera, Feng Gao, David G. Mutch, Katherine S. Virgo, Randall K. Gibb and Frank E. Johnson. How Physician Age Affects Surveillance Intensity after Primary Ovarian Cancer Treatment. British Journal of Medicine & Medical Research 9(10): 1-7, 2015, Article no. BJMMR.16127, ISSN: 2231-0614, 17th July 2015.
60. Shalowitz DI, Smith AG, Bell MC, Gibb RK. Teleoncology For Gynecologic Cancers. Gynecol Oncol. 2015 Oct;139(1):172-7.

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 17

61. Wolfson AH, Reis IM, Portelance L, Diaz DA, Zhao W, Gibb RK. Prognostic Impact Of Clinical Tumor Size On Overall Survival For Subclassifying Stages I And II Vaginal Cancer: A SEER Analysis. Gynecol Oncol. 2016 May;141(2):255-9. doi: 10.1016/j.ygyno.2016.03.009.
62. Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP), Ko EM, Havrilesky LJ, Alvarez RD, Zivanovic O, Boyd LR, Jewell EL, Timmins PF 3rd, Gibb RK, Jhingran A, Cohn DE, Dowdy SC, Powell MA, Chalas E, Huang Y, Rathbun J, Wright JD. Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30130-6. doi: 10.1016/j.ygyno.2018.02.010. [Epub ahead of print]

Abstracts: 1. Gibb RK, Gercel-Taylor C, Taylor D. Regulation of apoptosis associated with cisplatin and

taxol

therapy in ovarian cancer cell lines. Presented at the 27th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA. February 1996.

2. Gercel-Taylor C, Gibb RK, Taylor D. Effect of all-trans retinoic acid on the apoptosis induced by cisplatin and taxol in ovarian cancer cell lines. Presented at the 27th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA. February 1996.

3. Gibb RK, Gercel-Taylor C, Taylor D, Doering D. Association of WAF-1 and mdm-2 with the apoptotic response to cisplatin and taxol in ovarian cancer cell lines. Presented at the Annual Meeting of the American Association for Cancer Research, Washington, D.C. April 1996.

4. Gercel-Taylor C, Gibb RK, Taylor DD. Effect of all trans retinoic acid on the apoptosis induced by cisplatin and taxol in ovarian cancer cell lines. Presented at the Annual Meeting of the American Association for Cancer Research, Washington, D.C. April 1996.

5. Taylor DD, Gibb RK, Gercel-Taylor C. Hormone sensitive lipase induction as a mechanism of cancer cachexia. Presented at the Annual Meeting of the American Association for Cancer Research, Washington, D.C. April 1996.

6. Gibb RK, Gercel-Taylor C, Taylor DD, O'Connor DM, Doering DL. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Presented at the Second Annual Health Sciences Center Research Forum, University of Louisville School of Medicine, Louisville, KY. April 1996.

7. Tran C., Mutch D., Gibb RK, Virgo K., Johnson F. Geographic Variation in Surveillance Methods after Curative-Intent Primary Treatment for Ovarian Carcinoma.

8. Patel A.Y., Gao F., Mutch D.G, Gibb R.K., Virgo K.S., Johnson F.E., How Surgeon Age Affects Surveillance after Curative-Intent Primary Treatment for Ovarian Carcinoma.

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 18

9. Jonna S.R., Mutch D.G., Gao F., Gibb R.K., Virgo K.S., Johnson F.E. Effect of Initial Patient Prognosis on Surveillance Strategies after potentially Curative Treatment for Ovarian Cancer.
10. Makhija SK, Gibb RK, Gercel-Taylor C. Ovarian carcinoma chemotherapy induced apoptosis in monolayer versus spheroid cultures. Presented at the Second Annual Health Sciences Center Research Forum, University of Louisville School of Medicine, Louisville, KY. April 1996.
11. Gibb RK, Gercel-Taylor C, Taylor D, Doering D. Resistance to cisplatin and taxol as measured by apoptosis in ovarian cancer cell lines. Published in the 1996 Program/Proceedings of the American Society of Clinical Oncology.
12. Gercel-Taylor C, Gibb RK, Schneider C, Wan T, Taylor DD. Effect of mifepristone on endometrial cancer cell lines. Poster Presentation at the Annual Meeting of the Society for Gynecologic Investigation, San Diego, CA. March 1997. Published in Journal of the Society of Gynecologic Investigation 1997;4(1)Suppl. #360.
13. Gibb RK, Schneider C, Taylor D, Gercel-Taylor C. RU486 (Mifepristone) demonstrates growth inhibitory effects on endometrial carcinoma cell lines. Oral presentation at the 28th Annual Meeting of the Society of Gynecologic Oncologists, Phoenix, AZ. March 1997. Published in Gynecologic Oncology 1997;64(2):308, #75.
14. Metzinger D, Gibb RK, O'Connor D, Yashar CM, Taylor DD, Gercel-Taylor C. Expression of p53, bcl-2, bax, and WAF-1 Stage IIIc ovarian carcinoma. Society of Gynecologic Oncologists, Phoenix, AZ. March 1997. Published in Gynecologic Oncology 1997;64(2):331, #164.
15. Makhija SK, Gibb RK, O'Connor D, Doering D, Gercel-Taylor C. Regulation of chemotherapy-induced apoptosis in ovarian cancer cell spheroids. Presented at the Basic Science Program of the Annual Meeting of the Society of Gynecologic Oncologists, Phoenix, AZ. March 1997. Published in Gynecologic Oncology 1997;64(2):311, #86.

16. Gibb RK, O'Connor D, Katsanis W, Taylor D, Gercel-Taylor C. Mutational change in p53 arising in vivo as a mechanism of tumor progression in ovarian cancer. Presented at the Annual Meeting of the American Association for Cancer Research, San Diego, CA. April 1997. Published in *Gynecologic Oncology* 1997;64(2):332, #167.
17. Metzinger D, Shields L, Gibb RK, O'Connor D, Taylor D, Gercel-Taylor C. Prognostic significance of p53 bcl-2, bax, WAF-1 and mdm-2 in stage IIIc ovarian cancer. Presented at the Annual Meeting of the American Association for Cancer Research, San Diego, CA. April 1997.
18. Gercel-Taylor C, Wan T, Gibb RK, Makhija S, Taylor D. Regulation of apoptosis-related genes in ovarian cancer cell spheroids. Presented at the Annual Meeting of the American Association for Cancer Research, San Diego, CA. April 1997.

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 19

19. Metzinger D, Gibb RK, Shields L, Taylor DD, O'Connor D, Gercel-Taylor C. Differential expression of apoptosis-related genes in ovarian cancer. University of Louisville Health Sciences Center Research Forum, Louisville, KY. April 1997.
20. Gibb RK, Schneider C, Taylor DD, Gercel-Taylor C. Potential of RU486 (Mifepristone) in treatment of endometrial cancer. University of Louisville Health Sciences Center Research Forum, Louisville, KY. April 1997.
21. Schneider C, Gibb RK, Taylor DD, Gercel-Taylor C. Effect of Mifepristone on endometrial cancer cell lines. University of Louisville Health Sciences Center Research Forum, Louisville, KY. April 1997.
22. Schneider C, Gibb RK, Taylor DD, Gercel-Taylor C. Growth inhibition of endometrial carcinoma cell lines by RU486. The American College of Obstetricians and Gynecologists, District V,

Toronto, Canada. October 1997. (Won 1st Place Award)

23. Gibb RK, Mehta S, Taylor DD, Gercel-Taylor C. Regulation of apoptosis by RU486 (Mifepristone) in endometrial cancer cell lines. Society of Gynecologic Oncologists, Orlando, FL. February 1998.
24. Schneider C, Gibb RK, Taylor DD, Gercel-Taylor C. Growth inhibition of endometrial carcinoma cell lines by RU486. The American College of Obstetricians and Gynecologists Annual Clinical Meeting, New Orleans, LA. May 1998. (Won 1st Place - The Richardson Award)
25. Cohn, DE, Horowitz, NS, Herzog, TJ, Mutch, DG, Rader, JS, Bhalla, S, Gibb RK. The Significance of Pneumatosis Intestinalis or Bowel Perforation in Patients with Gynecologic Malignancies. 32nd Annual Meeting of the Society of Gynecologic Oncologists, Nashville, TN. March 2001. Abstract #88.
26. Horowitz, NS, Gibb RK, Menegakis, NE, Mutch, DG, Rader, JS, Herzog, TJ. Utility and cost-effectiveness of preoperative autologous blood donation in a university based gynecologic oncology practice. 32nd Annual Meeting of the Society of Gynecologic Oncologists, Nashville, TN. March 2001, Abstract #90.
27. Gibb RK. Prevalence and Impact of Clinical Comorbidity in Gynecologic Malignancies. 32nd Annual Meeting of the Society of Gynecologic Oncologists, Nashville, TN. March 2001. Abstract #338.
28. Gibb RK, Herzog, TJ, Bufford, HL, Mutch, DG, Rader, JS, Piccirillo, JF. Prevalence and Impact of Clinical Comorbidity in Gynecologic Malignancies. 32nd Annual Meeting of the Society of Gynecologic Oncologists, Nashville, TN. March 2001. Abstract #39.

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 20

29. Powell MA, Horowitz NS, Mutch DG, Rader JS, Gibb RK, Herzog TJ. Clinical and pathologic analysis of uterine papillary serous carcinoma (UPSC and the importance of lymphovascular space

invasion. 2002 SKB Fellow's Forum. February 2002.

30. Horowitz, NS, Mutch, DG., Gibb, RK, Herzog, TJ, Rader, JS, Kim SM, Manolitsas, TP, Fowler,

JM, Cohn David. Lymphovascular space invasion (LVSI) can be used to assign patients to radiation or lymphadenectomy as adjuvant therapy for unstaged endometrial cancer. 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL. March 2002. Abstract #622.

31. Horowitz NS, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Pinto KR, Goodfellow PJ. MSI, hMLH1

methylation and loss of mismatch repair analysis in endometrial cancer and atypical hyperplasia. 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL. March 2002. Abstract #631.

32. Gibb, RK, Impact of clinical comorbidity in the decision to treat ovarian cancer patients with

adjuvant chemotherapy. 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL. March 2002. Abstract #672.

33. Herzog TJ, Rader, JS, Gibb, RK, Powell, MA, Lippmann, LT, Accario, C, Mutch, DG. Phase II Study of Three-Day Topotecan for Recurrent Primary Peritoneal and Epithelial Ovarian Cancer in Platinum Sensitive Patients. 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL. March 2002. Abstract #682.

34. Herzog TJ, Hua, J, Horowitz, NS, Gibb, RK, Mutch, DG. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: An In Vitro Study. 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL. March 2002. Abstract #683.

35. Wright J, Gerhard, DS, Zhang, A, Huettner, PC, Trinkaus, KM, Mutch, DG, Herzog, TJ, Gibb, RK, Rader, JS. Molecular/Environmental markers as prognostic factors in early stage cervical carcinoma. 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL. March 2002. Abstract #759.

36. Whitcomb, BP, Powell, MA, Herzog, TJ, Pfeifer, JD, Rader, JS, Gibb, RK, Mutch, DG. Paget's disease of the vulva and vagina: Are positive margins predictive of recurrence? 41st Annual Meeting, American College of Obstetricians and Gynecologists Armed Forces District. October 2002.

37. Whitcomb, BP, Mutch, DG, Herzog, TJ, Rader, JS, Gibb, RK, Goodfellow, PJ. Frequent HOXA11 and THBS2 Promoter Methylation and a Methylator Phenotype in Endometrial Adenocarcinoma. 41st Annual Meeting, American College of Obstetricians and Gynecologists Armed Forces District. October 2002.

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 21

38. Wright J, Gerhard, DS, Zhang, A, Huettner, PC, Trinkaus, KM, Mutch, DG, Herzog, TJ, Gibb, RK, Rader, JS. Molecular/Environmental markers as prognostic factors in early stage cervical carcinoma. *Gynecologic Oncology* 2002; 84:524.

39. Whitcomb, BP, Mutch, DG, Herzog, TJ, Rader, JS, Gibb, RK, Goodfellow, PJ. Frequent HOXA11 and THBS2 Promoter Methylation and a Methylator Phenotype in Endometrial Adenocarcinoma. *Gynecologic Oncology Fellow's Forum*. February 2003.

40. Wright JD, Powell MA, Huettner PC, Mutch DG, Rader JS, Gibb RK, Herzog TJ.
Appendiceal

tumors mimicking ovarian cancer. Poster presentation 34th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA. February 2003.

41. Wright JD, Powell, MA, Huettner, PC, Mutch, DG, Rader, JS, Gibb RK, Herzog, TJ. Synchronous ovarian metastases at the time of laparotomy for colon cancer. 34th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA. February 2003. Abstract #185.

42. Whitcomb, BP, Powell, MA, Herzog, TJ, Pfeifer, JD, Rader, JS, Gibb RK, Mutch DG. Paget's disease of the vulva and vagina: Are positive margins predictive of recurrence? 34th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA. February 2003. Abstract #24.

43. Buttin, BM, Powell, MA, Goodfellow, PJ, Rader, JS, Lewin, SN, Herzog, TJ, Gibb RK. The role

of perioperative colon screening in patients with MSI-positive endometrial carcinoma. 34th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA. February 2003. Abstract #56.

44. Buttin, BM, Powell, MA, Mutch, DG, Rader, JS, Herzog, TJ, Gibb, RK, Goodfellow, PJ.

Increased risk for HNPCC-associated synchronous and metachronous malignancies in patients with MSI-positive endometrial carcinoma lacking MLH1 promoter methylation. 34th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA. February 2003. Abstract #57.

45. Buttin, BM, Powell, MA, Mutch, DG, Rader, JS, Herzog, TJ, Gibb, RK, Goodfellow, PJ.

Increased risk for HNPCC-associated synchronous and metachronous malignancies in patients with MSI-positive endometrial carcinoma lacking MLH1 promoter methylation. Glaxo SmithKline 2003 National Gynecologic Oncology Fellows' Forum, Phoenix, AZ. February 2003

46. Whitcomb, BP, Mutch, DG, Herzog, TJ, Rader, JS, Gibb, RK, Goodfellow, PJ. Frequent HOXA11 and THBS2 Promoter Methylation and a Methylator Phenotype in Endometrial Adenocarcinoma. 34th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA. February 2003. Abstract #65.

47. Gibb RK, Sadeghi S, Powell, MA, Herzog, TJ, Rader, JS, Mutch, DG. Liquid based cytology collection is superior to saline collection of pelvic washings in cellularity and cell preservation.

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 22

Oral presentation. 34th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA. February 2003. Abstract #95.

48. Wright JD, Herzog TJ, Davila R, Mutch DG, Rader JS, Gibb RK, Powell MA, Cohn DE. Liquid based cytology for the follow-up of women with gynecologic malignancies treated with radiation. Poster presentation. 34th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA. February 2003.

49. Powell MA, Wright JD, Gibb RK, Mutch DG, Rader JS, Herzog TJ. Morbidity of cytoreductive surgery in the elderly. Poster presentation. Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. June 2003.
50. Powell MA, Pfeifer JD, Buttin BS, Gibb RK, Luck MB, Rader JS. A pilot study of celecoxib in the treatment of patients with cervical and vaginal intraepithelial neoplasia. Poster presentation Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. June 2003.
51. Horowitz NS, Powell MA, Mutch DG, Rader JS, Gibb RK, Smith JK, Herzog TJ. Comprehensive staging of grade 1 endometrial cancers: Saving dollars and lives. Poster presentation. Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. June 2003.
52. Wright JD, Herzog TJ, Davila R, Mutch DG, Rader JS, Gibb RK, Powell MA, Cohn DE. Liquid based cytology for the follow-up of women with gynecologic malignancies treated with radiation. Poster presentation. 51st Annual Clinical Meeting of the American College of Obstetricians and Gynecologists. April 2004. 53. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Herzog TJ. Pelvic masses in obese women. Poster presentation. 51st Annual Clinical Meeting of the American College of Obstetricians and Gynecologists. April 2004.
54. Powell MA, Wright JD, Mutch DG, Rader JS, Gibb RK, Herzog TJ. Ovarian cancer: Obesity associated with prolonged survival. Poster presentation. Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. June 2004.
55. Virgo KS, Quang Y, Gibb R, Mutch D, Johnson FE. Costs of post-treatment surveillance for patients with ovarian cancer. Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. June 2005. Published in the Journal of Clinical Oncology 2005; 123(16S):489s.
56. Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippman L, Coleman RL, Mutch DG. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2008 Dec;111(3):467-73. doi: 10.1016/j.ygyno.2008.08.005.Epub 2008 Oct 1.
57. Nguyen TT, Wright JD, Powell MA, Gibb RK, Rader JS, Allsworth JE, Mutch DG. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. Int J

- Gynecol Cancer. 2008 Nov-Dec;18(6):1194-9. doi: 10.1111/j.1525-1438.2007.01184.x. Epub 2008 Jan 23.
58. Zigelboim I, Schmidt AP, Gao F, Thaker PH, Powell MA, Rader JS, Gibb RK, Mutch DG, Goodfellow PJ. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. *J Clin Oncol*. 2009 Jul 1;27(19):3091-6. Doi: 10.1200/JCO.2008.19.9802. Epub 2009 May 26. Erratum in: *J Clin Oncol* 2009 Oct 1;27(28)P:4819.
59. Harmandayan GZ, Gao F, Mutch DG, Virgo KS, Gibb RK, Johnson FE. Ovarian cancer patient surveillance after curative-intent initial treatment. *Gynecol Oncol*. 2011 Feb;120(2):205-8. doi: 10.1016/j.ygyno.2010.028.
60. Gibb RK, Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. *Rev Obstet Gynecol*. 2011;4(Suppl 1):S2-S11.
61. Gibb RK. The use of liquid-based cytology in cervical cancer screening. *Rev Obstet Gynecol*. 2011;4(Suppl 1):S1. No abstract available.
62. Gibb RK. The use of liquid-based cytology in cervical cancer screening. *Rev Obstet Gynecol*. 2011;4(Suppl 1):S1.
63. Johnson FE, Harmandayan GZ, Gao F, Virgo KS, Gibb RK, Mutch DG. Ovarian cancer patient surveillance after curative-intent initial treatment. Proceedings of the 25th Annual Meeting of the Association of VA Surgeons, April 10-11-2011, Irvine, CA. Abstract #31.
64. Gibb RK. What motivates expert clinicians who perform Patient Surveillance After Curative-Intent Treatment for Ovarian Cancer? N.N. Jamaluddin, K.S. Virgo, F. Gao, D.G. Mutch, R.K. Gibb, F. E. Johnson; Saint Louis University Medical Center, Saint Louis, MO; Washington University Medical Center, Saint Louis, MO; American Cancer Society, Atlanta, GA;

Department of Veterans Affairs Medical Center, St. Louis, MO. 2013

65. Johnson, F.E., Avino, R.J., **Gibb, R.K.**, Mutch, D.G., Gao, F., & Virgo, K.S. Surveillance after

curative-intent ovarian cancer treatment: The impact of HMOs. American Society of Clinical Oncology annual meeting, Chicago, IL. *Journal of Clinical Oncology*, 32 (Suppl.), e16530. 2014.

66. Singla, V, Gibb RK. Post treatment surveillance for ovarian carcinoma patients: The effects of HMO penetration rate. American College of Surgeons Clinical Congress. October 2014.

Invited Publications (editorials, reviews, chapters, including participation in committee reports in print or other media)

Book Chapters:

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 24

1. Katsanis WA, Gibb RK, Obralic N, Doering DL. Endometrial cancer. In Djulbegovic B, Sullivan D (eds). *Decision Making in Oncology: Evidence Based Management*. New York, NY: Churchill Livingstone, 1997:277-282.
2. Katsanis WA, Gibb RK, Obralic N, Doering DL. Vulvar cancer. In Djulbegovic B, Sullivan D (eds). *Decision Making in Oncology: Evidence Based Management*. New York, NY: Churchill Livingstone, 1997:299-303.
3. Obralic N, Katsanis WA, Gibb RK, Doering DL. Cervical cancer. In Djulbegovic B, Sullivan D (eds). *Decision Making in Oncology: Evidence Based Management*. New York, NY: Churchill Livingstone, 1997:283-287.
4. Gibb RK, Katsanis WA. Uterine cancer. In Ling F, Duff P (eds). *Obstetrics and Gynecology: Principles for Practice*. New York: McGraw-Hill, 2001.
5. Katsanis WK, Gibb RK. Gestational trophoblastic disease. In Ling F, Duff P (eds). *Obstetrics and Gynecology: Principles for Practice*. New York: McGraw-Hill, 2001.

6. Taylor NP, Gibb RK. Increasing abdominal girth. In Tietz Applied Laboratory Medicine, Second Edition. John Wiley & Sons, Inc. In press.
7. Gibb RK, Taylor NP. Size greater than dates. In: Tietz Applied Laboratory Medicine, Second Edition. John Wiley & Sons, Inc. In press.
8. Gibb RK, Olawaiye AB, Chen L, Grigsby PW, Hagemann IS, Wolfson AH, Zaino R, Mutch, DG. Chapter 50 Vulva. Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017. Pages 633-640.
9. Gibb RK, Olawaiye AB, Chen L, Grigsby PW, Hagemann IS, Wolfson AH, Zaino R, Mutch DG. Chapter 51 Vagina. Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017. Pages 641-647.
10. Prat J, Olawaiye AB, Bermudez A, Chen L, Copeland LJ, Gibb RK, Powell MA, Mutch DG. Chapter 55 Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma. Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017. Pages 681-690.

Other Invited
Publications:

1. Gibb RK, Controversies in Advanced Ovarian Cancer, Importance of Surgical Staging, Cytoreduction, and the Timing of Chemotherapy. Contemporary Oncology, June 1, 2002 Vol.1, Number 7.

Updated July,
2019

Randall K. Gibb, M.D. Curriculum Vitae Page 25

2. Gibb RK, Herzog TJ Changing Landscape of Cervical Cancer Screening and Implications. OB/GYN News Supplement, January 1, 2005. Elsevier.

Updated July,

